Revvity Agrees To Acquire ACD/Labs, Terms Undisclosed; Transaction Expected To Close Late In Q4 2025

Acquisition deepens Revvity Signals' presence in research informatics while furthering its ongoing expansion into development and manufacturing solutions

Revvity, Inc. (NYSE:RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals' solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to accelerate scientific innovation. The transaction is expected to close late in Q4 2025.